Ocaliva Exit Could Help Ipsen And Gilead’s New Cholangitis Entrants

 
• By Andrew McConaghie
  
Gilead
Gilead and Ipsen/Genfit's products could benefit from an EU withdrawal of the drug. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip